• john-liebler-antibodies-blue-amber

    Proven Science.

    Breakthrough Medicines.

A Bold Mission

Syntimmune’s mission is to leverage its position as the leader in FcRn science to create drugs that block the machinery driving IgG-mediated autoimmune diseases. We aim to provide profound, long-lasting benefit that has rapid onset and is easily reversible, to help patients who suffer from these diseases.

The Leader in FcRn Science

Syntimmune’s founders and advisors comprise the world’s leaders in the science of the neonatal Fc receptor (FcRn), a trafficking receptor that plays a key role in adaptive and innate immunity, including the regulation of antibody levels. The presence of pathogenic antibodies drives many autoimmune diseases. Our deep mechanistic understanding of the target biology of FcRn enables us to create medicines with high specificity that modulate distinct functions of FcRn, with powerful impact on a wide variety of diseases.

SYNT001

Lead drug candidate

30+ years

Proven scientific research on FcRn

$28M

Total committed capital

Advances in the Fight Against Autoimmune Disease

Syntimmune is a clinical-stage biopharmaceutical company advancing a range of drug candidates. Our lead molecule, SYNT001, targets the interaction between FcRn and IgG, modulating both adaptive and innate immunity and their roles in a wide range of autoimmune diseases.

Leadership

Syntimmune is headed by renowned entrepreneurs and scientists.

Portrait of Burt Adelman
Burt Adelman, M.D.
Senior Advisor, Director
laur1
Laurence Blumberg, M.D.
Business Founder, Director and Chief Operating Officer
richard
Richard Blumberg, M.D.
Scientific Founder, Director and Chairman of the Scientific Advisory Board
david-degraaf
David De Graaf, Ph.D.
President and CEO
Background

Latest News

Background

Ready to start the conversation?